Photo from wikipedia
Highlights • AIs may offer prolonged disease stability even in metastatic ESS, but response rates are modest.• After disease progression on one AI, some patients may benefit from trial of… Click to show full abstract
Highlights • AIs may offer prolonged disease stability even in metastatic ESS, but response rates are modest.• After disease progression on one AI, some patients may benefit from trial of a different AI.• Optimal duration of therapy is unclear; results of a phase 2 study on interruption vs maintenance of AI in LGESS are awaited.
Keywords:
role aromatase;
low grade;
aromatase inhibitors;
inhibitors treatment;
treatment low;
evaluating role
Journal Title: Gynecologic Oncology Reports
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Gynecologic Oncology Reports
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!